Ocular Therapeutix, Inc.
Open: 2:57 PM
OCUL Stock Price Graph
OCUL Stock Price Today
Ocular Therapeutix, Inc. (OCUL) stock rallied over 9.61% intraday to trade at $2.51 a share on NASDAQ. The stock opened with a gain of 6.55% at $2.44 and touched an intraday high of $2.48, rising 9.61% against the last close of $2.29. The Ocular Therapeutix, Inc. in stock market went to a low of $2.39 during the session.
OCUL Stock Snapshot
Number of Shares
Cash Flow per Share
Free Float in %
OCUL Stock Price History Chart
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Frequently Asked Questions
What is the current Ocular Therapeutix, Inc. (OCUL) stock price?
Ocular Therapeutix, Inc. (NASDAQ: OCUL) stock price is $2.51 in the last trading session. During the trading session, OCUL stock reached the peak price of $2.48 while $2.39 was the lowest point it dropped to. The percentage change in OCUL stock occurred in the recent session was 9.61% while the dollar amount for the price change in OCUL stock was $0.22.
OCUL's industry and sector of operation?
The NASDAQ listed OCUL is part of Biotechnology industry that operates in the broader Healthcare sector. Ocular Therapeutix, Inc. , a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology.
Who are the executives of OCUL?
Ms. Tracy Smith
Vice President of HR
Mr. Antony Mattessich
Pres, Chief Executive Officer & Director
Mr. Antony Mattessich
Pres, CEO & Director
Mr. Philip C. Strassburger Esq.
How OCUL did perform over past 52-week?
OCUL's closing price is 1.37% higher than its 52-week low of $2.23 where as its distance from 52-week high of $7.96 is -0.09%.
How many employees does OCUL have?
Number of OCUL employees currently stands at N/A. OCUL operates from 24 Crosby Drive, Bedford, MA 01730, US.
Link for OCUL official website?
Official Website of OCUL is: https://www.ocutx.com
How do I contact OCUL?
How many shares of OCUL are traded daily?
OCUL stock volume for the day was 756599.00 shares. The average number of OCUL shares traded daily for last 3 months was 770.69 Thousands.
What is the market cap of OCUL currently?
The market value of OCUL currently stands at $203.32 Million with its latest stock price at $2.51 and N/A of its shares outstanding.